{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:53:41Z","timestamp":1789707221405,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.rdc.2015.08.007","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T13:21:48Z","timestamp":1448284908000},"page":"47-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Corticosteroids in Lupus"],"prefix":"10.1016","volume":"42","author":[{"given":"Shanthini","family":"Kasturi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa R.","family":"Sammaritano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2015.08.007_bib1","first-page":"229","article-title":"Treatment of disseminated lupus erythematosus with cortisone and adrenocorticotropin","volume":"26","author":"Baehr","year":"1950","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.rdc.2015.08.007_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.1952.02930280017006","article-title":"Corticotropin and cortisone treatment for systemic lupus erythematosus","volume":"149","author":"Dubois","year":"1952","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.rdc.2015.08.007_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jama.1956.02970050029007","article-title":"Prednisone and prednisolone in the treatment of systemic lupus erythematous","volume":"161","author":"Dubois","year":"1956","journal-title":"J\u00a0Am Med Assoc"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.007_bib4","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J\u00a0Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib5","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib6","first-page":"S126","article-title":"Glucocorticoids in systemic lupus erythematosus","volume":"29","author":"Mosca","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.007_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780220901","article-title":"Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus","volume":"22","author":"Albert","year":"1979","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.autrev.2012.12.001","article-title":"The use of glucocorticoids in systemic lupus erythematosus. After 60 years still more an art than science","volume":"12","author":"Luijten","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.007_bib10","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/0961203309103870","article-title":"The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients","volume":"18","author":"Zhou","year":"2009","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.007_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0085-2538(15)50895-8","article-title":"Clinical significance of fever in the systemic lupus erythematosus patient receiving steroid therapy","volume":"68","author":"Rovin","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.007_bib12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF02230354","article-title":"Lymphadenopathy in systemic lupus erythematosus. Prevalence and relation to disease manifestations","volume":"15","author":"Shapira","year":"1996","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.rdc.2015.08.008","article-title":"Corticosteroids in Lupus Nephritis and Central Nervous System (CNS) Lupus","author":"Kamen","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.007_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0002-9378(77)90466-5","article-title":"In\u00a0vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta","volume":"127","author":"Blanford","year":"1977","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.007_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/ar1957","article-title":"Anti-inflammatory and immunosuppressive drugs and reproduction","volume":"8","author":"\u00d8stensen","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0022-3476(85)80259-6","article-title":"Prednisolone excretion in human milk","volume":"106","author":"Ost","year":"1985","journal-title":"J\u00a0Pediatr"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","article-title":"Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies","volume":"62","author":"Park-Wyllie","year":"2000","journal-title":"Teratology"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.007_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MJT.0b013e3182491e02","article-title":"Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring","volume":"21","author":"Bay Bjorn","year":"2014","journal-title":"Am J Ther"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/ar3433","article-title":"Mechanisms of B cell autoimmunity in SLE","volume":"13","author":"D\u00f6rner","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib20","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2010.60","article-title":"T\u00a0cells as therapeutic targets in SLE","volume":"6","author":"Crispin","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/BOR.0b013e3283546703","article-title":"Lupus neutrophils","volume":"24","author":"Knight","year":"2012","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.007_bib22","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.4049\/jimmunol.1102404","article-title":"Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease","volume":"188","author":"Leffler","year":"2012","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.rdc.2015.08.007_bib23","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.007_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ncprheum0898","article-title":"Genomic and nongenomic effects of glucocorticoids","volume":"4","author":"Stahn","year":"2008","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.rdc.2015.08.007_bib25","unstructured":"Strand V, Buttgereit F, McCabe D, et\u00a0al. A phase 2, randomized, double-blind comparison of the efficacy and safety of PF-04171327 (1, 5, 10, 15 mg QD) vs. 5 and 10 mg prednisone QD or placebo in subjects with rheumatoid arthritis (RA) over 8 weeks followed by a 4-week taper of study drug. In: American College of Rheumatology 2014 Meeting. Boston, MA, November 15-19, 2014. Late-Breaking Abstract L6."},{"issue":"2","key":"10.1016\/j.rdc.2015.08.007_bib26","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3899\/jrheum.090191","article-title":"Negative relationship between expression of glucocorticoid receptor alpha and disease activity: glucocorticoid treatment of patients with systemic lupus erythematosus","volume":"37","author":"Li","year":"2010","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2015.08.007_bib27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2005.048272","article-title":"Membrane glucocorticoid receptors are down regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1-independent expression pathway","volume":"65","author":"Spies","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2015.08.007_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0961203307079502","article-title":"High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus","volume":"16","author":"Parker","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.rdc.2015.08.007_bib29","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard.47.6.496","article-title":"A\u00a0double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus","volume":"47","author":"Mackworth-Young","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.007_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002922.pub2","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.007_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002265","article-title":"Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus","author":"Trevisani","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.rdc.2015.08.007_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard.46.10.773","article-title":"A\u00a0double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment","volume":"46","author":"Edwards","year":"1987","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1191\/0961203302lu243oa","article-title":"Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications","volume":"11","author":"Badsha","year":"2002","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1053\/sarh.2002.50003","article-title":"Intravenous pulses of methylprednisolone for systemic lupus erythematosus","volume":"32","author":"Badsha","year":"2003","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib35","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2015.08.007_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/0961203309356292","article-title":"Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis","volume":"19","author":"Walsh","year":"2010","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.007_bib37","doi-asserted-by":"crossref","first-page":"R108","DOI":"10.1186\/ar2763","article-title":"Flow cytometry analysis of glucocorticoid receptor expression and binding in steroid-sensitive and steroid-resistant patients with systemic lupus erythematosus","volume":"11","author":"Du","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.007_bib38","first-page":"339","article-title":"Glucocorticoid receptor beta splice variant expression in patients with high and low activity of systemic lupus erythematosus","volume":"45","author":"Piotrowski","year":"2007","journal-title":"Folia Histochem Cytobiol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/08916934.2013.830714","article-title":"Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study","volume":"46","author":"Zou","year":"2013","journal-title":"Autoimmunity"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib40","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/art.21032","article-title":"Clinical relevance of the expression of P-glycoprotein on peripheral blood lymphocytes to steroid resistance in patients with systemic lupus erythematosus","volume":"52","author":"Tsujimura","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7300","key":"10.1016\/j.rdc.2015.08.007_bib41","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature09102","article-title":"TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus","volume":"465","author":"Guiducci","year":"2010","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.007_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/ard.35.1.73","article-title":"Single daily dose corticosteroid treatment","volume":"35","author":"Myles","year":"1976","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib43","first-page":"944","article-title":"Intravenous pulse methylprednisolone followed by alternate day corticosteroid therapy in lupus erythematosus: a prospective evaluation","volume":"12","author":"Ballou","year":"1985","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2015.08.007_bib44","first-page":"57","article-title":"Flares in Lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone","volume":"33","author":"Danowski","year":"2006","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2015.08.007_bib45","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/j.jaad.2010.06.018","article-title":"Cutaneous lupus erythematosus: update of therapeutic options: part I","volume":"65","author":"Kuhn","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.007_bib46","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kei142","article-title":"\u201cNot only\u2026but also\u201d: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus","volume":"44","author":"Bruce","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.007_bib47","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/art.1780390303","article-title":"The development and initial validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology damage index for systemic lupus erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2015.08.007_bib48","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.007_bib49","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1002\/art.20622","article-title":"Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events","volume":"50","author":"Toloza","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a009122","article-title":"Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study","volume":"145","author":"Manzi","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/aje\/kws130","article-title":"Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus","volume":"176","author":"Magder","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.rdc.2015.08.007_bib52","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2015.08.007_bib53","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1186\/ar2764","article-title":"Predictors of major infections in systemic lupus erythematosus","volume":"11","author":"Ruiz-Irastorza","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.rdc.2015.08.007_bib54","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C","article-title":"Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data","volume":"42","author":"Ramsey-Goldman","year":"1999","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2015.08.007_bib55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1358\/dot.2012.48.8.1841300","article-title":"Important drug interactions in patients with rheumatic disorders: interactions of glucocorticoids, immunosuppressants, and antimalarial drugs","volume":"48","author":"Hromadkova","year":"2012","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.rdc.2015.08.007_bib56","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1345\/aph.1H418","article-title":"Effect of oral corticosteroids on chronic warfarin therapy","volume":"40","author":"Hazlewood","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.rdc.2015.08.007_bib57","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2125.2001.01372.x","article-title":"Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects","volume":"51","author":"Lebrun-Vignes","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rdc.2015.08.007_bib58","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.1K62B","article-title":"Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?","volume":"42","author":"Lam","year":"2008","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.rdc.2015.08.007_bib59","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","article-title":"EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases","volume":"72","author":"Duru","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2015.08.007_bib60","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","article-title":"Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)","volume":"72","author":"Buttgereit","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1500071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X1500071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:15:28Z","timestamp":1760181328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X1500071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0889857X1500071X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids in Lupus","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2015.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}